Systemic inflammatory response after bronchoalveolar lavage in critically ill patients

T.T. Bauer*, C. Arosio*, C. Montòn*, X. Filella*, A. Xaubet*, A. Torres*


ABSTRACT: Bronchoscopic bronchoalveolar lavage (BAL) may be followed by a systemic inflammatory response. Previous reports have suggested pneumonia as a predisposing condition and systemic cytokines as possible mediators.

To test this hypothesis, systemic levels of interleukin (IL)-1β, IL-6 and tumour necrosis factor-alpha (TNF-α) were studied before and at 12 h and 24 h after bronchoscopically guided BAL in 30 mechanically ventilated patients (median age 67 (range 54–76) yrs, simplified acute physiology score II (SAPS II) 33 (12–56)), 20 of whom had pneumonia and 10 of whom were control patients without pneumonia. Arterial oxygen partial pressure to inspired oxygen fraction ratio (PaO2/FI O2), body temperature, mean arterial pressure, and cardiac frequency were recorded. The majority of patients (28/30, 93%) received antibiotic treatment prior to the procedure.

PaO2/FI O2 ratio was lower at 12 h compared to baseline in patients with pneumonia (baseline median 192 (range 65 – 256); 12 h 160 (66 – 190) mmHg, p < 0.001) and ventilated controls (baseline 293 (205 – 473); 12 h 226 (153 – 330) mm Hg p = 0.011), but returned to baseline levels at 24 h (pneumonia: 194 (92 – 312), p = 0.591; controls: 309 (173 – 487) mmHg, p = 0.785). No changes in other clinical variables were observed. Systemic TNF-α levels before BAL (pneumonia: 35 (10 – 88); controls: 17 (0 – 33) pg·mL⁻¹) did not increase at 12 h (pneumonia: 35 (0 – 64); p = 0.735; controls: 16 (0 – 21) pg·mL⁻¹, p = 0.123 comparison to baseline) or 24 h (pneumonia: 31 (0 – 36), p = 0.464; controls: 19 (0 – 43) pg·mL⁻¹, p = 0.358). No changes of IL-1β (baseline: pneumonia 0 (0 – 13); controls 1 (0 – 32) pg·mL⁻¹) or IL-6 (baseline: pneumonia, 226 (9 – 4300); controls, 53 (0 – 346) pg·mL⁻¹) were detected.

No deterioration of clinical variables and no increase in systemic cytokine release has been observed after bronchoalveolar lavage, in critically ill patients. The cytokine increase is probably too small, in relation to the pre-existing inflammatory response, to yield clinical significance in this population otherwise antibiotic therapy may have been protective.


Fibreoptic procedures, and particularly bronchoalveolar lavage (BAL), are important diagnostic tools, and tolerance is generally good. Side effects such as serious arrhythmia, bleeding, pneumonia, or pneumothorax are rare [1] and acute haemodynamic effects are small even in critically ill intubated patients [2].

However, in some cases, BAL may be followed by myalgia, headache or even fever [3]. A systematic follow-up after bronchoscopically guided BAL suggested that this systemic inflammatory response, or sepsis-like syndrome, is caused by a proinflammatory cytokine release [4]. This study in noncritically ill patients, however, excluded patients with pneumonia, and did not assess the bacterial burden of the lungs. Translocation of bacterial products [5] or even entire micro-organisms [6] from the lungs to the bloodstream, however, may play a crucial role for the pyrogenic response after BAL, particularly in the presence of mechanical ventilation.

Systemic cytokine levels have therefore been studied after bronchoscopically guided BAL in mechanically ventilated patients, with and without pneumonia.

Materials and methods

This trial was conducted in an 850-bed tertiary care hospital between January 1 1995 and December 31 1997. All patients on ventilatory support for more than 48 h in one respiratory intensive care unit (RICU) were eligible for the study. Patients were included consecutively if they fulfilled clinical criteria of pneumonia: presence of new infiltrates on the chest radiograph and two of the following criteria: fever ≥ 38.3 °C, purulent secretions, leukocytosis (≥ 12,000·mm⁻³) or leucopenia (≤ 4,000·mm⁻³). Pneumonia was classified as community-acquired (occurring < 72 h into stay) or nosocomial (≥ 72 h). The ventilated control group without pneumonia included patients who met the following criteria: 1) mechanical ventilatory support for more than 48 h;
2) absence of any infectious process; or 3) absence of any of the criteria of the pneumonia group. Bronchoscopy was indicated for other reasons (e.g. tube malposition, minor haemoptysis or visual inspection of the tracheobronchial tree) in patients without pneumonia.

Exclusion criteria were: 1) unstable clinical condition (e.g. cardiac arrhythmia, acute ischemic heart disease, need for vasoactive drugs); 2) known increased intracranial pressure; 3) small diameter endotracheal tube (< 7 mm); 4) acute respiratory distress syndrome (ARDS); 5) cerebral injury; or 6) coagulation’s disorders. The study was approved by Ethical Committee of our Centre and in each case informed consent was obtained from the next of kin.

Protocol

The following demographic, clinical, and laboratory data were recorded from all patients: age; gender; underlying disease; cause of ICU admission; duration of mechanical ventilation before the study; use of corticosteroids (any i.v. administration during 24 h prior to sampling); prior antibiotic use (administered i.v. for more than 24 h); blood analyses necessary for calculations of the simplified acute physiology score (SAPS II) [7]. Antipyretic medication (e.g. nonsteroid anti-inflammatory drugs) was not used 24 h prior to the study and was also withheld during the 24 h follow-up period.

Arterial oxygenation expressed as arterial partial pressure of oxygen/inpired fraction of oxygen (PaO2/FIO2), arterial blood pressure, cardiac frequency (fC) and axillary body temperature were sequentially recorded and for the purpose of this study were documented before and at 12 h and 24 h after BAL. An increase in body temperature of ≥1 °C within the 24 h follow-up was defined as significant.

Blood sampling

Arterial blood samples were collected anaerobically, through an indwelling polyethylene catheter (Seldicath, Plastimed; Saint-Leu-La-Foët, France) inserted into the radial artery, before, 12 h and 24 h after BAL, for blood gas and cytokine analyses. These time points were selected because in previous observations, serum tumour necrosis factor-alpha (TNF-α) levels after a fibreoptic procedure were detectable as early as 4 h after the procedure, peaked at 24 h, and returned to undetectable levels by 48 h [8]. Samples for blood gases were immersed in ice and processed within 5 min in a blood gas analyser (ABL77 Radiometer, Copenhagen, Denmark). Cytokine samples were collected in sterile tubes without additive and after clotting, were centrifuged at 3,500 × g for 10 min. Serum was aspirated and stored at -70 °C until processing. Venous blood samples drawn before and 12 h and 24 h after BAL were cultured for bacterial and fungal pathogens according to standard methods [9].

Bronchoalveolar lavage (BAL)

Patients were sedated before the fibreoptically guided BAL (Pentax FB18, Asahi Optical Ltd., Japan). No local anaesthetics were administered and suction was carefully avoided until the bronchoscope had been wedged in the designated position. A special endotracheal adapter was used in order to continue mechanical ventilation. Patients were ventilated with volume control during bronchoscopy and ventilator settings were readjusted to pre-BAL values thereafter. During bronchoscopy FIO2 was set to 100% and reduced according to clinical conditions after 1 h. Up to five aliquots of 30 mL physiologic saline were instilled (range 90 – 150 mL) and the first aspirated portion was discarded. BAL fluid was subjected to microbiological analyses and only pathogens known to cause respiratory infections (potentially pathogenic micro-organisms, PPMs) are reported here.

Cytokine assays

The following cytokines were determined: TNF-α, interleukin-1β (IL-1β) and interleukin-6 (IL-6). Solid phase enzyme-linked immunosorbent assay (ELISA) was employed, based on the quantitative immunometric sandwich enzyme immunoassay technique on a microtitre plate (EASIA: Enzyme Amplified Sensitivity Immunoassay, Medgenix Diagnostics SA, Fleurus, Belgium). This ELISA method used a murine monoclonal antibody specific for the particular cytokine to be analysed, coated onto the microtitre plate to create the solid phase. Serum specimens were pipetted into the wells in duplicate. After the cytokine was bound to the immobilised antibody, a second monoclonal antibody was added to the wells and allowed to bind to a different epitope on the same cytokine. Horseradish peroxidase enzyme was conjugated to the monoclonal antibody. After an incubation period, a sandwich was formed. The enzyme substrate chromagen tetramethylbenzidine was then added and colour developed in proportion to the amount of the particular cytokine bound to the plate. Colour development was stopped with H2SO4, and colourimetric determination was done by means of a polychromic reader (EASIA Reader, Medgenix Diagnostics SA, Fleurus, Belgium). Concentrations of cytokines from samples were determined by comparing the optical densities of the samples to the standard curves. Results are expressed as pg mL⁻¹ of serum. The sensitivity of the technique allows the detection of levels as low as 3 pg mL⁻¹ for TNF-α and 2 pg mL⁻¹ for IL-1β and IL-6, respectively. The following values are regarded as upper limits for cytokine concentrations in normal controls in our laboratory: IL-6 5 pg mL⁻¹; TNF-α 20 pg mL⁻¹; and IL-1β 15 pg mL⁻¹.

Statistical analysis

Results are expressed as median and range because of the nonparametric distribution of the data. The Mann-Whitney U-test was employed for the comparison of
quantitative variables between two groups. Changes over time were assessed by Wilcoxon test for paired differences. Proportions were compared by Chi-squared test or Fisher’s exact test where appropriate. The level of significance was set to \( p \leq 0.05 \) for all analyses (all two-tailed).

**Results**

A total of 30 patients were included in the study, 20 (67%) with pneumonia according to the predefined criteria and 10 control patients without pneumonia (33%) (table 1). Pneumonia was nosocomial in 12/20 patients (60%) and community acquired in 8/20 patients (40%). All 20 patients with pneumonia and 8 without pneumonia had received antibiotic drugs prior to BAL. Antibiotics were indicated in control patients for extrapulmonary infections or perioperative infection prophylaxis. Underlying diseases in the pneumonia group included cardiac disease (n = 4), chronic obstructive pulmonary disease (COPD, n = 5), stroke (n = 2), miscellaneous (n = 6), and none (n = 3). In the control group underlying diseases included: COPD (n = 5), miscellaneous (n = 3), and none (n = 2). Corticosteroid medication had been given to 16/30 (53%) patients prior to the sampling procedure, mainly for bronchial dilatation, without significant differences between patients with pneumonia and controls (table 1).

Within the pneumonia group, methylprednisolone had been given for a median 7.5 (1–18) days in a median cumulative dose of 550 (160–1605) mg. The median duration of therapy was 5 (3–8) days in the control group (p = 0.859) and the median cumulative dose of 360 (160–705) mg (p = 0.440). The mortality observed during RICU stay was 43% (13/30 patients), with a slightly higher mortality among patients with pneumonia (10/20, 50% versus 3/10, 30%) (p = 0.297).

Microbiological data were available in 18/20 (90%) patients with pneumonia and all controls. A total of 7/18 (39%) specimens were sterile. The following PPMs were recovered in the group of patients with pneumonia: *Pseudomonas aeruginosa* (n = 2), *Acinetobacter baumanii* (n = 1), *Enterobacter spp.* (n = 2), *Staphylococcus aureus* (n = 2), *Streptococcus pneumoniae* (n = 2), and *Aspergillus fumigatus* (n = 2). BAL cultures of control patients without pneumonia were sterile or showed no growth for PPMs in 8/10 cases (80%). One BAL showed growth for *P. aeruginosa* and *S. aureus*, respectively.

Blood cultures were sterile in all but one patient (29/30, 97%). The pre-BAL blood culture was negative in this particular patient with nosocomial pneumonia, whereas follow-up blood cultures at 12 h and at 24 h showed growth for *Streptococcus epidermidis*. This micro-organism was also isolated in the BAL fluid of the patient.

**Clinical variables**

The variation of the \( P_aO_2/F_IO_2 \) ratio over time for patients with pneumonia and control patients is summarized in figure 1. The \( P_aO_2/F_IO_2 \) ratio dropped significantly in both groups after the BAL and was significantly lower in patients with pneumonia compared to controls at any time point (p = 0.001, all time points).

The comparison between patients with pneumonia and controls for mean arterial pressure (MAP), axillary

<table>
<thead>
<tr>
<th>Table 1.—Clinical data of patients investigated</th>
</tr>
</thead>
<tbody>
<tr>
<td>With pneumonia (n = 20)</td>
</tr>
<tr>
<td>-------------------------</td>
</tr>
<tr>
<td>Age yrs</td>
</tr>
<tr>
<td>Gender male, n (%)</td>
</tr>
<tr>
<td>SAPS II</td>
</tr>
<tr>
<td>( P_aO_2/F_IO_2 )</td>
</tr>
<tr>
<td>Duration of mechanical ventilation prior to the study, h</td>
</tr>
<tr>
<td>Leukocyte count, ( \times 10^9 )L(^{-1} )</td>
</tr>
<tr>
<td>Corticosteroids, n (%)</td>
</tr>
<tr>
<td>Prior antibiotics, n (%)</td>
</tr>
<tr>
<td>Mortality, n (%)</td>
</tr>
</tbody>
</table>

All patients received mechanical ventilation during the study and pneumonia was defined according to clinical criteria. Data are presented as median (range) unless otherwise stated.*: Mann–Whitney U-test and Chi-squared or Fisher’s exact test for quantitative and categorical variables, respectively. SAPS II: simplified acute physiology score II; \( P_aO_2/F_IO_2 \): arterial oxygen partial pressure to inspired oxygen fraction ratio.
body temperature and \( f^\circ C \) are illustrated in figure 2. The MAP tended to fall in patients with pneumonia during the first 12 h (\( p \approx 0.070 \)), but increased again thereafter. No changes were observed in control patients during the follow-up period. A total of 7/30 patients (23%, 3 patients with pneumonia and 4 controls) showed an increase of \( >1^\circ C \) in body temperature during follow-up. The MAP was different at baseline between patients with pneumonia and controls (\( p \approx 0.172 \)), but was significantly higher in controls at 12 h (\( p \approx 0.014 \)) and at 24 h (\( p \approx 0.001 \)), compared to patients with pneumonia.

Axillary body temperature increased significantly, only in control patients at 12 h (\( p = 0.042 \)) and 24 h after BAL (\( p = 0.021 \); fig. 2). Mean values of axillary body temperature were only significantly different between patients with pneumonia and controls before BAL (\( p = 0.01 \), but not at 12 h (\( p = 0.699 \)) or 24 h (\( p = 0.410 \); fig. 2).

No significant changes were observed for \( f^\circ C \) after BAL, neither in patients with pneumonia or the control group (fig. 2). Patients with pneumonia had a higher average \( f^\circ C \) compared to control patients before BAL (\( p = 0.005 \)) and at 12 h (\( p = 0.009 \)) and 24 h (\( p = 0.009 \) after BAL.

**Systemic cytokine levels**

Baseline levels of TNF-\( \alpha \) and IL-6 were significantly higher in pneumonia patients compared to controls, reflecting the inflammatory process. However, systemic cytokine expression in serum did not change significantly after BAL in our patients. There was a trend for IL-1\( \beta \) to increase at 24 h and IL-6 tended to fall at this time point (table 2). These changes were caused mainly by the patients in the pneumonia group. The concentration of TNF-\( \alpha \) and IL-6 in serum was higher in patients with pneumonia compared to control patients at all time points (table 2), but this was not the case for IL-1\( \beta \).

**Subanalysis**

Data were reanalysed according to the recovery of PPMs in the BAL, because all patients with pneumonia were pre-treated with antibiotics. The results are summarized in table 3. No significant changes over time, or for the comparison of patients with and without pathogens in the lavage, were found.

Pneumonia patients and controls were analysed separately for the comparison of subjects with and without an increase of \( >1^\circ C \) in body temperature during follow-up, to avoid bias introduced by differences in baseline cytokine levels. Among control patients with an increase in body temperature, only serum IL-6 was significantly higher after 12 h compared to control patients without an increase in body temperature (with increase 81 (51 – 159) pg.mL\(^{-1} \), no increase 17 (12 – 55) pg.mL\(^{-1} \), \( p = 0.032 \)). No significant differences for baseline cytokine levels were observed for this comparison. In patients with pneumonia, analysis revealed that those who developed an increase in body temperature showed significantly higher values of TNF-\( \alpha \) 24 h after BAL (with increase 61 (59 – 63) pg.mL\(^{-1} \), no increase 25 (0 – 49) pg.mL\(^{-1} \), \( p = 0.019 \)).

In another subanalysis, cytokine levels were compared for patients with and without corticosteroid medication also separated for pneumonia patients and controls. In control patients, no differences were found for this comparison in either baseline cytokine levels or during follow-up. Among the patients with pneumonia, baseline serum levels of IL-6 were lower in patients with corticosteroids, compared to those without pneumonia at baseline (with corticosteroids 97 (9 – 2600) pg.mL\(^{-1} \), no corticosteroids 914 (35 – 4300) pg.mL\(^{-1} \), \( p = 0.031 \)).
and at 12 h follow-up (with corticosteroids 78 (16 – 2560) pg·mL⁻¹, no corticosteroids 982 (33–3778) pg·mL⁻¹, p ~ 0.041).

**Discussion**

The findings of this study do not support the hypothesis that pneumonia is a predisposing condition leading to development of a systemic inflammatory response after BAL. This conclusion is based on observations that: 1) bronchoscopically guided BAL in critically ill patients was not associated with clinically significant changes of MAP, body temperature or °C at 12 h or 24 h, regardless of the presence of pneumonia; 2) there was no increase in systemic cytokine release after bronchoscopically guided BAL at 12 h and 24 h in either patients with pneumonia or in controls; 3) a systemic inflammatory response after BAL in patients with pneumonia did not depend on the presence or absence of bacterial pathogens in BAL fluid.

**Table 2.** – Mean systemic cytokine levels before bronchoalveolar lavage (BAL), and 12 h and 24 h thereafter for all the patients and separately for patients with pneumonia and controls

<table>
<thead>
<tr>
<th>Concentration pg·mL⁻¹</th>
<th>Before BAL</th>
<th>12 h</th>
<th>24 h</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>All patients (n = 30)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TNF-α</td>
<td>22 (0 – 88)</td>
<td>19 (0 – 64)</td>
<td>25 (0 – 63)</td>
</tr>
<tr>
<td>IL-1β</td>
<td>0 (0 – 32)</td>
<td>0 (0 – 31)</td>
<td>2 (0 – 122)*</td>
</tr>
<tr>
<td>IL-6</td>
<td>108 (0 – 4300)</td>
<td>84 (12 – 3778)</td>
<td>112 (5 – 1976)</td>
</tr>
<tr>
<td><strong>With pneumonia (n = 20)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TNF-α</td>
<td>35 (10 – 88)</td>
<td>35 (0 – 64)</td>
<td>31 (0 – 36)</td>
</tr>
<tr>
<td>IL-1β</td>
<td>0 (0 – 13)</td>
<td>3 (0 – 31)</td>
<td>5 (0 – 122)*</td>
</tr>
<tr>
<td>IL-6</td>
<td>226 (9 – 4300)</td>
<td>156 (16 – 3778)</td>
<td>194 (11 – 1976)</td>
</tr>
<tr>
<td><strong>Controls (n = 10)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TNF-α</td>
<td>17 (0 – 33)</td>
<td>15.5 (0 – 21)</td>
<td>19 (0 – 43)</td>
</tr>
<tr>
<td>IL-1β</td>
<td>1 (0 – 32)</td>
<td>0 (0 – 13)</td>
<td>0 (0 – 7)</td>
</tr>
<tr>
<td>IL-6</td>
<td>53 (0 – 346)</td>
<td>55 (12 – 159)</td>
<td>46 (5 – 296)</td>
</tr>
<tr>
<td><strong>p-values</strong> for comparison between patients with and controls</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TNF-α</td>
<td>0.010</td>
<td>0.002</td>
<td>0.037</td>
</tr>
<tr>
<td>IL-1β</td>
<td>&gt; 0.2</td>
<td>&gt; 0.2</td>
<td>&gt; 0.2</td>
</tr>
<tr>
<td>IL-6</td>
<td>0.017</td>
<td>0.021</td>
<td>0.074</td>
</tr>
</tbody>
</table>

Values were compared at different time points and between patients with and without pneumonia (exact p-values are given if p < 0.2). Data are presented as median (range). TNF-α: tumour necrosis factor α; IL: interleukin; *: p = 0.150 versus baseline; #: p = 0.054 versus control; +: p = 0.123 versus baseline; #: p = 0.068 versus baseline; §: p-value calculated with Mann-Whitney U-Test.

**Table 3.** – Comparison of clinical and cytokine data between patients with pneumonia and recovery of a potentially pathogenic micro-organism (PPM) in bronchoalveolar lavage (BAL), and patients with pneumonia and sterile BAL cultures

<table>
<thead>
<tr>
<th></th>
<th>Before BAL</th>
<th>12 h</th>
<th>24 h</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PPM recovered (n = 11)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean arterial blood pressure, mmHg</td>
<td>88 (67 – 110)</td>
<td>77 (65 – 108)</td>
<td>82 (73 – 100)</td>
</tr>
<tr>
<td>Axillary body temperature, °C</td>
<td>36.2 (35.6 – 37.6)</td>
<td>37.0 (35.8 – 38.6)</td>
<td>36.8 (36.2 – 38.0)</td>
</tr>
<tr>
<td>Cardiac frequency beats·min⁻¹</td>
<td>95 (80 – 145)</td>
<td>100 (75 – 125)</td>
<td>105 (70 – 135)</td>
</tr>
<tr>
<td>TNF-α, pg·mL⁻¹</td>
<td>39 (13 – 88)</td>
<td>41 (0 – 64)</td>
<td>37.5 (13 – 63)</td>
</tr>
<tr>
<td>IL-1β, pg·mL⁻¹</td>
<td>2 (0 – 12)</td>
<td>2 (0 – 14)</td>
<td>2 (0 – 122)</td>
</tr>
<tr>
<td>IL-6, pg·mL⁻¹</td>
<td>297 (47 – 4300)</td>
<td>359 (53 – 3778)</td>
<td>194 (23 – 924)</td>
</tr>
<tr>
<td><strong>BAL sterile or no PPM (n = 7)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean arterial blood pressure, mmHg</td>
<td>68 (57 – 107)</td>
<td>70 (57 – 110)</td>
<td>73 (62 – 112)</td>
</tr>
<tr>
<td>Axillary body temperature, °C</td>
<td>37.2 (35.8 – 38.0)</td>
<td>36.4 (35.8 – 38.0)</td>
<td>36.8 (35.0 – 38.8)</td>
</tr>
<tr>
<td>Cardiac frequency beats·min⁻¹</td>
<td>85 (60 – 115)</td>
<td>90 (50 – 105)</td>
<td>85 (80 – 110)</td>
</tr>
<tr>
<td>TNF-α, pg·mL⁻¹</td>
<td>22 (10 – 47)</td>
<td>25 (14 – 44)</td>
<td>23.5 (0 – 48)</td>
</tr>
<tr>
<td>IL-1β, pg·mL⁻¹</td>
<td>0 (0 – 13)</td>
<td>2 (0 – 31)</td>
<td>4 (0 – 43)</td>
</tr>
<tr>
<td>IL-6, pg·mL⁻¹</td>
<td>78 (9 – 1424)</td>
<td>53 (16 – 1487)</td>
<td>43 (11 – 596)</td>
</tr>
</tbody>
</table>

Data are presented as median (range). TNF-α: tumour necrosis factor α; IL: interleukin; PPM: potentially pathogenic micro-organism. *: microbiological results were not available in 2/20 (10%) patients with pneumonia. No significant differences were observed for the comparison between time points or between patients with and without recovery of a PPM.
are associated with these sepsis-like symptoms are not known, although they may occur in as many as 30% of
the fibreoptically guided procedures [3]. Previous
reports, however, suggested that the release of pro-
inflammatory cytokines may be involved.

PUGIN and SUETER [13] investigated clinical effects of a
fibreoptically guided BAL in critically ill patients with
and without pneumonia. They found a significant
increase in body temperature and decrease in MAP
after the procedure in patients with pneumonia but not
in controls. Changes in body temperature correlated
significantly with those in MAP, and also with the level
of endotoxin in bronchoscopic BAL fluid. These
findings suggested that BAL, in critically ill patients
with pneumonia, may have caused intravascular
translocation of toxins or mediators producing pyro-
genic and hypotensive effects. The data from the
present study supports this hypothesis only in part,
because no general increase in the systemic inflam-
matary response, as measured by cytokine levels, could be
found at 12 h or 24 h. Similarly, no statistically or
clinically significant changes in body temperature,
MAP or fever could be found after the bronchoscopically
guided BAL. It is plausible that differences from the
previous study are accounted for by the fact that all but
two of our patients had received antibiotic treatment
before sampling. Systemic cytokine release, associated
with bacterial translocation, may have been blunted by
this treatment. On the other hand, one might also argue
that the increase in body temperature reported by
PUGIN and SUETER [13] was less likely due to the
diagnostic procedure, but due to pneumonia. However,
when patients with and without an increase in body
temperature ≥1°C during the follow-up period were
compared, an increase in IL-6 in control patients after
12 h was seen that was no longer significant after 24 h.
It is likely that a transient inflammatory response was
described in this subgroup of patients without pneu-
monia, that may have been associated with the
diagnostic procedure. This should be confirmed,
though, in a larger cohort, because the number of
control patients in the present study was small, and the
definition of a temperature increase had to be arbitrary.

A significant systemic cytokine release after BAL has
been observed in previous studies involving noncriti-
cally ill patients. In a report of a normal healthy
volunteer who underwent bronchoscopy and BAL, STANDIFORD et al. [8] showed rising TNF-α levels
associated with clinical symptoms after the interven-
tion. KRAUSE et al. [4] systematically compared the
systemic inflammatory response after bronchoscopy
with and without BAL in 50 patients, with a variety of
pulmonary conditions including pulmonary metastasis
or bronchial carcinoma. They found an increase of
systemic levels of IL-1β and IL-6 at 6 h in all patients,
although the increase seemed to be more pronounced in
the BAL group. Baseline cytokine levels, however, were
low in this noncritically ill population and the mean
increase was 27.5 pg mL⁻¹ for IL-6. Regarding the
present study in critically ill patients, an increase of this
magnitude was not detectable, and probably not
clinically important, because e.g. the IL-6 median
level was already more than 30-fold at baseline
(108 pg mL⁻¹) compared to the baseline median
(3.71 pg mL⁻¹) reported in the study by KRAUSE et al.
[4] (table 2). In addition, TNF-α levels and particularly
IL-6 levels were already well above the normal upper
limits for healthy controls at baseline.

This study included one case of possible transloca-
tion of S. epidermidis from the pulmonary compart-
ment to the bloodstream after BAL in a 74-yr old
female with bilateral nosocomial pneumonia, who had
been on mechanical ventilation with zero positive end-
expiratory pressure (PEEP) for more than 24 h.
Bacteraemia has been described after rigid broncho-
scopy, but has never been documented after fibreoptic
procedures in humans [4, 14]. Animal data suggest that
this route of dissemination may have been facilitated by
mechanical ventilation [6] or injury to the alveolar
epithelium [15]. VERBRUGGE et al. [16] determined the
effect of PEEP on the development of bacteraemia with
Klebsiella pneumoniae after mechanical ventilation of
intratracheally inoculated rats, and concluded that
10 cmH₂O PEEP reduced ventilation-induced K. pneu-
monia bacteraemia. Nevertheless, a causal relationship
between the fibreoptic procedure cannot be confidently
assumed from the present study, since bacteraemia is
a common finding in patients with nosocomial pneu-
monia, or it may have occurred spontaneously
[17]. In addition, S. epidermidis is not a common
nosocomial pathogen and the assumed translocation
from alveolar space to bloodstream may have been
unrelated to the underlying inflammatory process.
Furthermore, when the systemic inflammatory response
was analysed with respect to the presence or absence of
potentially pathogenic micro-organisms in the BAL
fluid, no significant differences in the systemic inflam-
matory response after bronchoscopically guided BAL
were found.

One might argue that this study simply missed the
increase in the systemic inflammatory response, because
only two time points were assessed (12 h and 24 h).
However, KRAUSE et al. [4] observed differences at 6 h
and the well documented case report suggested a peak
response at 24 h. However, it cannot be ruled out that
short-term changes were missed due to the study design,
or changes in the local inflammatory response because
patients were not investigated with a follow-up
bronchoscopy. A major confounding factor in this
study was probably the antibiotic treatment. In fact a
trend was even observed towards lower IL-6 levels at
24 h, which could possibly reflect the adequacy of
treatment and the decreasing systemic inflammatory
response. Nevertheless, it is important not to extra-
polate the results to a population without pre-emptive
antibiotic therapy. To assist bronchodilatation, a
considerable proportion of the patients had received
corticosteroids prior to the study, which have been
shown to interfere with cytokine levels [18]. The
comparison between patients with and without cortico-
steroid treatment was hampered by substantial differ-
ences in cytokine levels at baseline between patients
with pneumonia and controls, as it has been described
previously [18]. A multivariate analysis would have
been interesting to separate effects of BAL and
corticosteroids on cytokine kinetics. However, the
present study was too small to allow a reasonable
application of this statistical method.
In conclusion, whereas bronchoscopically guided bronchoalveolar lavage seems to be associated with a clinically significant systemic cytokine release in the noncritically ill patient, no general confirmation of this finding in a population of intubated and mechanically ventilated patients could be made. One possible explanation may be that the magnitude of the induced systemic inflammatory response may be insignificant in critically ill patients with high baseline cytokine levels. A transient increase in interleukin-6 levels was observed among patients without pneumonia after 12 h when patients with and without an increase in body temperature were compared, but limitations apply to this subanalysis. Future trials should assess whether antibiotic or corticosteroid pre-treatment has any effect on the systemic inflammatory response after bronchoscopic procedures.

References